 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PainReform reveals superior IVR rates of PRF-110 vs. competitors in post-surgical pain management. Findings showcase PRF-110's extended analgesic effect potential, reducing opiate dependency.
read...

EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PainReform reaches 50% enrollment in second part of Phase 3 trial of PRF-110

Remains on track to announce top-line data by mid-2024TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform files to sell shares

Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL AVIV, Israel, March 01, 2024 (GLOBE...

PainReform Provides Year-End Business Update

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...

PainReform to Present at the Microcap Conference in Atlantic City

Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ('PainReform' or the 'Company'), a clinical-stage specialty pharmaceutical company focused on the reformulation...

PainReform files to sell 968,545 ordinary shares for holders

PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreadingTEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Volume (M)	570,988.00
52-Wk High	$26.41
52-Wk Low	$0.69

PRFX PainReform Ltd

About

Feed

News

Fundamentals